AZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLAstraZeneca has announced data showing its cancer drug Calquence outperformed standard care in chronic lymphocytic leukaemia – reducing Share XAZ prepares for showdown with AbbVie/J&J as Calquence shines in CLLhttps://pharmaphorum.com/news/az-prepares-for-showdown-with-abbvie-jj-as-calquence-shines-in-cll/
bluebird offers instalment payments for Zynteglo gene therapybluebird bio is pricing its thalassaemia gene therapy Zynteglo at €1.57 million ($1.8 million) in Europe, but with Share Xbluebird offers instalment payments for Zynteglo gene therapyhttps://pharmaphorum.com/news/bluebird-offers-instalment-payments-for-zynteglo-gene-therapy/
EU safety experts begin review of leuprorelin-containing drugsEuropean safety experts are to begin a review of leuprorelin-containing medicines, commonly used in breast and prostate cancer Share XEU safety experts begin review of leuprorelin-containing drugshttps://pharmaphorum.com/news/eu-safety-experts-begin-review-of-leuprorelin-containing-drugs/
Three drugmakers challenge Trump’s price disclosure rulingAmgen, Merck & Co and Eli Lilly have launched a legal challenge to a new rule that will Share XThree drugmakers challenge Trump’s price disclosure rulinghttps://pharmaphorum.com/news/three-drugmakers-challenge-trumps-price-disclosure-ruling/
Lilly’s Taltz scrapes win against Humira in psoriatic arthritisEli Lilly’s Taltz has beaten AbbVie’s blockbuster Humira in a psoriatic arthritis study involving patients who hadn’t been Share XLilly’s Taltz scrapes win against Humira in psoriatic arthritishttps://pharmaphorum.com/news/lillys-taltz-scrapes-win-against-humira-in-psoriatic-arthritis/
CVS Health funds insomnia app, stop smoking support could followThe influential US pharmacy benefit manager CVS Health has said it will fund an insomnia app, allowing it Share XCVS Health funds insomnia app, stop smoking support could followhttps://pharmaphorum.com/news/cvs-health-funds-insomnia-app-stop-smoking-and-abuse-support-could-follow/
FDA approves Herceptin biosimilar as US patent expiresThe FDA has approved Amgen and Allergan’s biosimilar of Roche’s Herceptin, just in time for the breast cancer Share XFDA approves Herceptin biosimilar as US patent expireshttps://pharmaphorum.com/news/fda-approves-herceptin-biosimilar-as-us-patent-expires/
Teva expands blood pressure drug recall in the US amid cancer fearsTeva has expanded a recall of losartan potassium tablets after tests revealed a potential human carcinogen in the Share XTeva expands blood pressure drug recall in the US amid cancer fearshttps://pharmaphorum.com/news/teva-expands-blood-pressure-drug-recall-in-the-us-amid-cancer-fears/
GSK makes CRISPR play, funding Doudna lab in CaliforniaGlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new Share XGSK makes CRISPR play, funding Doudna lab in Californiahttps://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/
